Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Heidelberg Pharma AG's Enterprise Value is €94.42 Mil.
Heidelberg Pharma AG's Free Cash Flow for the trailing twelve months (TTM) ended in May. 2026 was €-24.87 Mil. Therefore, Heidelberg Pharma AG's EV-to-FCF for today is -3.80.
The historical rank and industry rank for Heidelberg Pharma AG's EV-to-FCF or its related term are showing as below:
XTER:HPHA'
s EV-to-FCF Range Over the Past 10 Years
Min: -26.24 Med: -5.15 Max: -1.63
Current: -3.94
During the past 13 years, the highest EV-to-FCF of Heidelberg Pharma AG was -1.63. The lowest was -26.24. And the median was -5.15.
XTER:HPHA's EV-to-FCF is ranked worse than 100% of 336
companies
in the Biotechnology industry
Industry Median: 15.32
vs XTER:HPHA: -3.94
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Heidelberg Pharma AG (XTER:HPHA) EV-to-FCF Explanation
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Heidelberg Pharma AG's PE Ratio (TTM) for today is calculated as:
Heidelberg Pharma AG's share price for today is €2.55.
Heidelberg Pharma AG's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in May. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €-0.711.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Heidelberg Pharma AG EV-to-FCF Related Terms
Heidelberg Pharma AG EV-to-FCF Historical Data
* Premium members only.
The historical data trend for Heidelberg Pharma AG's EV-to-FCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
XTER:HPHA vs VRTX, REGN, ALNY: EV-to-FCF Comparison
For the Biotechnology subindustry, Heidelberg Pharma AG's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Heidelberg Pharma AG EV-to-FCF vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Heidelberg Pharma AG's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where Heidelberg Pharma AG's EV-to-FCF falls into.
Heidelberg Pharma AG's current Enterprise Value is €94.42 Mil.
Heidelberg Pharma AG's Free Cash Flow for the trailing twelve months (TTM) ended in May. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €-24.87 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Heidelberg Pharma AG (XTER:HPHA) has a EV-to-FCF of -3.80 as of Jul. 16, 2026. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Heidelberg Pharma AG and its competitors. According to the industry distribution chart, Heidelberg Pharma AG ranks #999999 out of 336 companies in the Biotechnology industry.
Is Heidelberg Pharma AG's EV-to-FCF too high?
Heidelberg Pharma AG's current EV-to-FCF is -3.80. Based on the distribution chart, Heidelberg Pharma AG ranks #999999 out of 336 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Heidelberg Pharma AG has a GF Score™ of 32/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Heidelberg Pharma AG's EV-to-FCF compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Heidelberg Pharma AG ranks #999999 out of 336 companies for EV-to-FCF. This places Heidelberg Pharma AG in the lower half of its industry. The industry median EV-to-FCF is 15.32. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-FCF for a Biotechnology company?
The median EV-to-FCF among Biotechnology companies is 15.32, based on 336 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-FCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-FCF mean?
A high EV-to-FCF can signal that a stock is expensive relative to its fundamentals. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Heidelberg Pharma AG and its competitors. For the Biotechnology industry, the median EV-to-FCF is 15.32 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Heidelberg Pharma AG's current EV-to-FCF is -3.80. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Heidelberg Pharma AG stock overvalued right now?
Based on GuruFocus' analysis, Heidelberg Pharma AG (XTER:HPHA) is currently considered Significantly Overvalued. The stock's GF Value™ is €0.96, compared to a current price of €2.55 — trading 165.6% above its estimated fair value. The current EV-to-FCF is -3.80. Heidelberg Pharma AG's overall GF Score™ is 32/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-FCF calculated?
EV-to-FCF is calculated from a company's financial statements. For Heidelberg Pharma AG (XTER:HPHA), the current EV-to-FCF is -3.80 as of Jul. 16, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Heidelberg Pharma AG (XTER:HPHA) Overvalued in 2026?
Based on GuruFocus' analysis, Heidelberg Pharma AG stock appears to be overvalued.
The current stock price of €2.55 is trading 165.6% above its estimated GF Value™ of €0.96.
GuruFocus considers Heidelberg Pharma AG to be Significantly Overvalued.
Key valuation signals for XTER:HPHA:
EV-to-FCF: -3.80
GF Value™: €0.96 vs. price of €2.55 (165.6% above fair value)
No single metric tells the full story. See the XTER:HPHA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Heidelberg Pharma AG is a biopharmaceutical company developing oncology treatments through antibody drug conjugates (ADCs), which combine antibody specificity with toxin potency to selectively target and kill cancer cells. The Company researches, develops, and produces these ADCs, and has built an ADC toolbox using various antibodies and payloads to address multiple cancers and overcome tumor resistance. Its activities focus on its proprietary ATAC technology based on Amanitin, the toxin of the death cap mushroom, leveraging its biological mechanism as a novel cancer therapy. The ATAC platform is used to develop proprietary ADC candidates and is also applied in collaborations with third parties.
32GF Score
Get the complete analysis for XTER:HPHA
EV-to-FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XTER:HPHA has been successfully added to your 
